The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Kanvas Bio Unveils Clinical Data on the Gut Microbiome’s Impact on Anti-Tumoral Immunity at SITC ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...